Loading…
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. (LYCA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in South San Francisco, United States and has 31 employees. The company is worth $1.56B. The share price is 17.8% below its 52-week high of $36.49. None of the 38 superinvestors we track reported it in their latest 13F. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in LYCA.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QUREuniQure N.V. | $22.43 | — | 4.8x | 0.00% | -157.61% | $1.56B |
| NTLAIntellia Therapeutics, Inc. | $11.21 | — | 2.2x | 0.00% | -55.44% | $1.57B |
| TRAXFirst Tracks Biotherapeutics, Inc. | $44.05 | — | 9.2x | 0.00% | — | $1.57B |
| PAHCPhibro Animal Health Corp | $38.80 |
| 16.0x |
| 4.1x |
| 1.24% |
| 29.72% |
| $1.58B |
| ABSIAbsci Corp | $9.18 | — | 6.4x | 0.00% | -57.72% | $1.58B |
| CERTCertara, Inc. | $10.33 | — | 1.6x | 0.00% | -2.21% | $1.58B |